- Home
- VNO vs HALO Comparison
VNO vs HALO Comparison
Compare VNO & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNO
- HALO
- Stock Information
- Founded
- VNO 1946
- HALO 1998
- Country
- VNO United States
- HALO United States
- Employees
- VNO N/A
- HALO N/A
- Industry
- VNO Real Estate Investment Trusts
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VNO Real Estate
- HALO Health Care
- Exchange
- VNO Nasdaq
- HALO Nasdaq
- Market Cap
- VNO 7.5B
- HALO 6.4B
- IPO Year
- VNO N/A
- HALO N/A
- Fundamental
- Price
- VNO $42.42
- HALO $49.00
- Analyst Decision
- VNO Hold
- HALO Buy
- Analyst Count
- VNO 11
- HALO 9
- Target Price
- VNO $34.07
- HALO $61.11
- AVG Volume (30 Days)
- VNO 1.5M
- HALO 2.2M
- Earning Date
- VNO 11-04-2024
- HALO 10-31-2024
- Dividend Yield
- VNO 2.83%
- HALO N/A
- EPS Growth
- VNO N/A
- HALO 61.71
- EPS
- VNO N/A
- HALO 3.02
- Revenue
- VNO $1,871,179,000.00
- HALO $947,355,000.00
- Revenue This Year
- VNO N/A
- HALO $23.36
- Revenue Next Year
- VNO $2.67
- HALO $15.15
- P/E Ratio
- VNO N/A
- HALO $16.21
- Revenue Growth
- VNO N/A
- HALO 21.35
- 52 Week Low
- VNO $21.16
- HALO $33.15
- 52 Week High
- VNO $46.63
- HALO $65.53
- Technical
- Relative Strength Index (RSI)
- VNO 53.63
- HALO 43.09
- Support Level
- VNO $39.20
- HALO $42.01
- Resistance Level
- VNO $41.27
- HALO $46.20
- Average True Range (ATR)
- VNO 1.56
- HALO 2.76
- MACD
- VNO -0.32
- HALO -1.08
- Stochastic Oscillator
- VNO 43.34
- HALO 34.74
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.